Navigation Links
Quorum Review IRB Launches New Quick Step™ Service for Large Clinical Trials
Date:7/22/2014

Seattle, WA (PRWEB) July 22, 2014

Quorum Review IRB, the industry leader in central IRB services, announces a new service for large clinical trials called Quick Step™. The offering went live on July 1, 2014 and is designed to address the research industry’s need for seamless study start-up with a large volume of researcher sites. The service is available for studies planning 50 or more North American investigator sites, as well as related studies with a combined planned North American site count of 80 or more. Qualifying studies may also enroll international sites after the minimum for North America is met.

The Quick Step™ program bundles efficiency features that only an IRB of Quorum’s expertise and size can offer. Quick Step™ includes a study manager that is assigned before IRB submission; five hours of complimentary regulatory consulting from one of Quorum’s six in-house attorneys; facilitated completion of our Central Study Questionnaire (CSQ); identification of potential sites for enrollment; and assisted site outreach. Additionally, for the purpose of site enrollment, Quorum can migrate certain site data from related studies already under Quorum’s oversight, as well as data from other IRB forms for studies being transferred to Quorum.

The first stage in Quick Step™ is the assignment of a Quorum Study Manager (in advance of study submission) to help clients expedite and customize their submission process for review. The Study Manager also helps clients determine how best to use their five hours of complimentary regulatory consulting—perhaps for protocol/consent discussion or international country selection. Quorum can populate the client’s submission forms and ensure they are taking full advantage of all efficiencies and customizations available to them.

Additional opportunities for customization and efficiency include custom document citations, consent form development, recruitment material processing prior to initial Board review, and complimentary tracking of amendment language into the consent form. Quick Step™ customers have access to research sites from Quorum’s Site Directory and assistance in outreach to potential sites. Quorum’s Outreach Program has been particularly successful at enrolling high numbers of Institutional sites with Quorum as the central IRB. Once Quick Step™ studies are in-house they are prioritized, and turnaround times are measured and reported to the respective client.

Quorum’s CEO Cami Gearhart says of the new service, “Quorum is very excited to offer this new suite of services that will make running these complex and important large clinical studies streamlined and simple.”

For more details on Quorum Review’s new Quick Step™ service, visit http://www.quorumreview.com/quickstep.

About Quorum Review IRB

Quorum Review is an independent institutional review board fully accredited by the Association for the Accreditation of Human Research Protection Programs (AAHRPP), and has been providing ethics review of human clinical research since 1992. Quorum oversees research in accordance with U.S. and Canadian human subject research protection regulations and guidelines set forth by the International Committee on Harmonisation (ICH), and principles of the Belmont Report.

Quorum’s best-in-class IRB services include 15 Board meetings each week plus expedited review, 24-hour site review turnaround, 36-hour amendment review turnaround, a secure Web Portal, and Smart Forms for online submissions. Quorum’s IRB service offerings include full study review in the US and Canada, international ethics review, a specialized Phase I team, and unique processes for minimal risk research.

Read the full story at http://www.prweb.com/releases/2014/07/prweb12021556.htm.


'/>"/>
Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related biology technology :

1. Quorum IRB Board Chair to Speak at South Korean Research Summit
2. Quorum Review’s Mitchell Parrish Presents at Embracing Change: Clinical Research in the 21st Century
3. Quorum Review IRB and ConsentSolutions Form Strategic Alliance
4. Quorum Review IRB Board Chair Appointed to SACHRP
5. A Critical Review of Analytical Techniques for Improved Living Standards
6. Panama’s First Umbilical Cord Stem Cell Clinical Trial for Rheumatoid Arthritis Approved by Comité Nacional de Bioética de la Investigación Institutional Review Board
7. Gordon Hunter’s ‘How Are You, Mother Earth?’ Receives Four Stars from Clarion Review
8. A Review of Cardiovascular Pressure Sensing and Relevant Performance Specifications to Ensure Data Integrity, a New and Upcoming Webinar Hosted by Xtalks
9. Scar Global Clinical Trials Review, H2, 2013
10. Acute Pain Global Clinical Trials Review, H2, 2013
11. Barretts Esophagus Global Clinical Trials Review, H2, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... ... , ... The Society for Immunotherapy of Cancer (SITC) strongly opposes the proposed ... fiscal year 2018 budget request. , This proposal calls for a ... roughly 20% of its total budget. If applied proportionally across NIH, funding for the ...
(Date:3/22/2017)... , March 22, 2017  RXi Pharmaceuticals ... innovative therapeutics that address significant unmet medical needs, ... Chief Business Officer, will present at the 5th ... will provide a platform to present to and ... leading pharmaceutical and biotech companies as well as ...
(Date:3/20/2017)... ... March 20, 2017 , ... ... and biotech companies, recently announced it will debut a brand new pressure vessel, ... The intelliVessel is controlled by a touch screen panel and features other revolutionary ...
(Date:3/20/2017)... , ... March 20, 2017 , ... The fourth annual ... while innovating to make an extraordinary impact on peoples’ lives, launches today. Sponsored by ... challenge every 5 weeks and awards thousands in cash prizes to engineers, inventors and ...
Breaking Biology Technology:
(Date:2/14/2017)... N.C. , Feb. 14, 2017  Wake Forest ... M.D., as its new chief executive officer (CEO). Freischlag ... CEO John D. McConnell , M.D., who last ... position at the Medical Center, after leading it since ... the full scope of Wake Forest Baptist,s academic health ...
(Date:2/10/2017)... Feb 10, 2017 Research and ... "Personalized Medicine - Scientific and Commercial Aspects" to ... ... Diagnosis is integrated with therapy for selection of treatment as ... detection and prevention of disease in modern medicine. Biochip/microarray technologies ...
(Date:2/8/2017)... 2017  Aware, Inc. (NASDAQ: AWRE ), a ... results for its quarter and year ended December 31, 2016. ... was $3.9 million compared to $6.9 million in the same ... 2016 was $0.6 million compared to $2.6 million in the ... of 2016 was $0.5 million, or $0.02 per diluted share, ...
Breaking Biology News(10 mins):